Filing Details
- Accession Number:
- 0001144204-16-124959
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-09-22 21:00:23
- Reporting Period:
- 2016-09-20
- Filing Date:
- 2016-09-22
- Accepted Time:
- 2016-09-22 21:00:23
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1270073 | Intercept Pharmaceuticals Inc | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1559569 | Mark Pruzanski | C/O Intercept Pharmaceuticals, Inc. 450 W. 15Th Street, Suite 505 New York NY 10011 | Ceo & President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-09-20 | 26,589 | $8.67 | 579,314 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2016-09-20 | 8,411 | $9.82 | 587,725 | No | 4 | M | Direct | |
Common Stock | Disposition | 2016-09-20 | 35,000 | $165.00 | 552,725 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Options to Purchase Common Stock | Disposition | 2016-09-20 | 26,589 | $0.00 | 26,589 | $8.67 |
Common Stock | Options to Purchase Common Stock | Disposition | 2016-09-20 | 8,411 | $0.00 | 8,411 | $9.88 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
90,039 | 2020-08-16 | No | 4 | M | Direct | |
0 | 2018-09-18 | No | 4 | M | Direct |
Footnotes
- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person.
- All shares underlying this option have vested.